question: AhR ligands are attractive drug targets for pharmaceutical development due to their induction of Cyp1a1, yes or no?
answer: Yes,  there is little evidence to support the indiscriminate exclusion of AhR activators/Cyp1a1 inducers from early drug developmental pipelines.